Stop • Prevent • Heal

Guarding gastrointestinal integrity, a major cornerstone of human health.


Leading BioSciences is leveraging more than three decades of academic research, as well as 13 years of the company’s own internal efforts, to develop novel therapeutics designed to improve human health through protection of the Gastrobiome.


Lead drug candidate LB1148, which is entering Phase 3 development, is a novel oral drug with the potential to improve return of gastrointestinal (GI) function and shorten patients’ length of stay in the hospital following major surgery.


More than 30 years of groundbreaking scientific research conducted at the University of California at San Diego and other prestigious academic institutions supports the importance of the Gastrobiome to overall human health and highlights the dangerous medical complications that can occur when its intestinal mucosal barrier is disrupted.


Leading BioSciences Announces Potential for Investigational Drug LB1148 to Treat Multiple Organ Dysfunction Syndrome in COVID-19 Patients

Leading BioSciences’ initial focus is accelerating postoperative return of gastrointestinal (GI) function to shorten patients’ length of stay in the hospital. Positive data from the company’s Phase 2 trial showed that LB1148 demonstrated a statistically significant improvement in return to bowel function and an overall decrease in ICU and hospital length of stay as compared to placebo.